202 related articles for article (PubMed ID: 20584868)
1. Lipoprotein(a) accelerates atherosclerosis in uremic mice.
Pedersen TX; McCormick SP; Tsimikas S; Bro S; Nielsen LB
J Lipid Res; 2010 Oct; 51(10):2967-75. PubMed ID: 20584868
[TBL] [Abstract][Full Text] [Related]
2. Antisense oligonucleotide directed to human apolipoprotein B-100 reduces lipoprotein(a) levels and oxidized phospholipids on human apolipoprotein B-100 particles in lipoprotein(a) transgenic mice.
Merki E; Graham MJ; Mullick AE; Miller ER; Crooke RM; Pitas RE; Witztum JL; Tsimikas S
Circulation; 2008 Aug; 118(7):743-53. PubMed ID: 18663084
[TBL] [Abstract][Full Text] [Related]
3. High levels of lipoprotein(a) in transgenic mice exacerbate atherosclerosis and promote vulnerable plaque features in a sex-specific manner.
Assini JM; Clark JR; Youssef A; Xing C; Doerfler AM; Park SH; Saxena L; Yaseen AB; Børen J; Gros R; Bao G; Lagor WR; Boffa MB; Koschinsky ML
Atherosclerosis; 2023 Nov; 384():117150. PubMed ID: 37290980
[TBL] [Abstract][Full Text] [Related]
4. Lipoprotein(A) with An Intact Lysine Binding Site Protects the Retina From an Age-Related Macular Degeneration Phenotype in Mice (An American Ophthalmological Society Thesis).
Handa JT; Tagami M; Ebrahimi K; Leibundgut G; Janiak A; Witztum JL; Tsimikas S
Trans Am Ophthalmol Soc; 2015; 113():T5. PubMed ID: 26538774
[TBL] [Abstract][Full Text] [Related]
5. High-level lipoprotein [a] expression in transgenic mice: evidence for oxidized phospholipids in lipoprotein [a] but not in low density lipoproteins.
Schneider M; Witztum JL; Young SG; Ludwig EH; Miller ER; Tsimikas S; Curtiss LK; Marcovina SM; Taylor JM; Lawn RM; Innerarity TL; Pitas RE
J Lipid Res; 2005 Apr; 46(4):769-78. PubMed ID: 15654123
[TBL] [Abstract][Full Text] [Related]
6. Changes in lipoprotein(a), oxidized phospholipids, and LDL subclasses with a low-fat high-carbohydrate diet.
Faghihnia N; Tsimikas S; Miller ER; Witztum JL; Krauss RM
J Lipid Res; 2010 Nov; 51(11):3324-30. PubMed ID: 20713651
[TBL] [Abstract][Full Text] [Related]
7. High-dose atorvastatin reduces total plasma levels of oxidized phospholipids and immune complexes present on apolipoprotein B-100 in patients with acute coronary syndromes in the MIRACL trial.
Tsimikas S; Witztum JL; Miller ER; Sasiela WJ; Szarek M; Olsson AG; Schwartz GG;
Circulation; 2004 Sep; 110(11):1406-12. PubMed ID: 15353498
[TBL] [Abstract][Full Text] [Related]
8. Percutaneous coronary intervention results in acute increases in oxidized phospholipids and lipoprotein(a): short-term and long-term immunologic responses to oxidized low-density lipoprotein.
Tsimikas S; Lau HK; Han KR; Shortal B; Miller ER; Segev A; Curtiss LK; Witztum JL; Strauss BH
Circulation; 2004 Jun; 109(25):3164-70. PubMed ID: 15184281
[TBL] [Abstract][Full Text] [Related]
9. Lipoprotein(a), Oxidized Phospholipids, and Coronary Artery Disease Severity and Outcomes.
Gilliland TC; Liu Y; Mohebi R; Miksenas H; Haidermota S; Wong M; Hu X; Cristino JR; Browne A; Plutzky J; Tsimikas S; Januzzi JL; Natarajan P
J Am Coll Cardiol; 2023 May; 81(18):1780-1792. PubMed ID: 37137588
[TBL] [Abstract][Full Text] [Related]
10. Experimental Animal Models Evaluating the Causal Role of Lipoprotein(a) in Atherosclerosis and Aortic Stenosis.
Yeang C; Cotter B; Tsimikas S
Cardiovasc Drugs Ther; 2016 Feb; 30(1):75-85. PubMed ID: 26780907
[TBL] [Abstract][Full Text] [Related]
11. A novel function of lipoprotein [a] as a preferential carrier of oxidized phospholipids in human plasma.
Bergmark C; Dewan A; Orsoni A; Merki E; Miller ER; Shin MJ; Binder CJ; Hörkkö S; Krauss RM; Chapman MJ; Witztum JL; Tsimikas S
J Lipid Res; 2008 Oct; 49(10):2230-9. PubMed ID: 18594118
[TBL] [Abstract][Full Text] [Related]
12. Relationship of oxidized phospholipids on apolipoprotein B-100 particles to race/ethnicity, apolipoprotein(a) isoform size, and cardiovascular risk factors: results from the Dallas Heart Study.
Tsimikas S; Clopton P; Brilakis ES; Marcovina SM; Khera A; Miller ER; de Lemos JA; Witztum JL
Circulation; 2009 Apr; 119(13):1711-9. PubMed ID: 19307470
[TBL] [Abstract][Full Text] [Related]
13. Oxidized phospholipids predict the presence and progression of carotid and femoral atherosclerosis and symptomatic cardiovascular disease: five-year prospective results from the Bruneck study.
Tsimikas S; Kiechl S; Willeit J; Mayr M; Miller ER; Kronenberg F; Xu Q; Bergmark C; Weger S; Oberhollenzer F; Witztum JL
J Am Coll Cardiol; 2006 Jun; 47(11):2219-28. PubMed ID: 16750687
[TBL] [Abstract][Full Text] [Related]
14. Low density lipoprotein receptor-negative mice expressing human apolipoprotein B-100 develop complex atherosclerotic lesions on a chow diet: no accentuation by apolipoprotein(a).
Sanan DA; Newland DL; Tao R; Marcovina S; Wang J; Mooser V; Hammer RE; Hobbs HH
Proc Natl Acad Sci U S A; 1998 Apr; 95(8):4544-9. PubMed ID: 9539774
[TBL] [Abstract][Full Text] [Related]
15. Heritability of Biomarkers of Oxidized Lipoproteins: Twin Pair Study.
Rao F; Schork AJ; Maihofer AX; Nievergelt CM; Marcovina SM; Miller ER; Witztum JL; O'Connor DT; Tsimikas S
Arterioscler Thromb Vasc Biol; 2015 Jul; 35(7):1704-11. PubMed ID: 25953646
[TBL] [Abstract][Full Text] [Related]
16. Association of Mild to Moderate Aortic Valve Stenosis Progression With Higher Lipoprotein(a) and Oxidized Phospholipid Levels: Secondary Analysis of a Randomized Clinical Trial.
Capoulade R; Yeang C; Chan KL; Pibarot P; Tsimikas S
JAMA Cardiol; 2018 Dec; 3(12):1212-1217. PubMed ID: 30476957
[TBL] [Abstract][Full Text] [Related]
17. Oxidized phospholipid modification of lipoprotein(a): Epidemiology, biochemistry and pathophysiology.
Koschinsky ML; Boffa MB
Atherosclerosis; 2022 May; 349():92-100. PubMed ID: 35606081
[TBL] [Abstract][Full Text] [Related]
18. The role of oxidized phospholipids in mediating lipoprotein(a) atherogenicity.
Tsimikas S; Witztum JL
Curr Opin Lipidol; 2008 Aug; 19(4):369-77. PubMed ID: 18607184
[TBL] [Abstract][Full Text] [Related]
19. Effect of therapeutic interventions on oxidized phospholipids on apolipoprotein B100 and lipoprotein(a).
Yeang C; Hung MY; Byun YS; Clopton P; Yang X; Witztum JL; Tsimikas S
J Clin Lipidol; 2016; 10(3):594-603. PubMed ID: 27206947
[TBL] [Abstract][Full Text] [Related]
20. Oxidized phospholipids in cardiovascular disease.
Tsimikas S; Witztum JL
Nat Rev Cardiol; 2024 Mar; 21(3):170-191. PubMed ID: 37848630
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
